Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Combination of Glimepiride/Vildagliptin/Metformin in T2D
NCT04841096Phase 3Completed
- Sponsor
- Laboratorios Silanes
- Start
- Mar 2023
- Primary completion
- Mar 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of glimepiride, vildagliptin, liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM), sponsored by Laboratorios Silanes. Started Mar 2023; status: completed.
02
Drugs
glimepiridevildagliptinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04841096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04841096.